The one-month return of Third Harmonic Bio, Inc. (NASDAQ:THRD) was 48.28%, and its shares lost 55.90% of their value over the last 52 weeks. On May 1, 2025, Third Harmonic Bio, Inc. (NASDAQ:THRD ...

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with resu ...

SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...

Third Harmonic Bio's only asset failed in a phase 1 safety trial, which paralyzes its clinical pipeline. Find out why I rate THRD stock a Sell.

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases ...

Third Harmonic Bio, which emerged from stealth early this year with a lead drug from Novartis and a $105 million round of funding, has not yet set any financial terms for its planned IPO.

Third Harmonic Bio shares were up 39%, trading around $5.06 at the time of publication Monday, according to Benzinga Pro. Read Next: S&P 500 Could Tank To 4,000 If ‘Trump Put’ Fizzles, Says ...

Third Harmonic Bio reported a $29.6 million loss in 2021 and a loss of $12.8 million in 2020, with no revenue yet generated. Clinical stage biopharmaceutical company Third Harmonic Bio Inc. on ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) is a biopharmaceutical company. The one-month return of Third Harmonic Bio, Inc. (NASDAQ:THRD) was 48.28%, and its shares lost 55.90% of their value over the ...

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN ...